AZN — ASTRAZENECA PLC catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

14 verified catalyst event(s) for ASTRAZENECA PLC (ticker AZN). Each is linked to its official source. Verified as of 2026-09-20.

Next verified catalyst

2026-09-30 — A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monal · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-09-30 in 10d ESTIMATED	READOUT A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab Phase 3 · Non-Small Cell Lung Cancer	AZN ASTRAZENECA PLC	Durvalumab, Oleclumab, Monalizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osime Phase 3 · Metastatic Non-small Cell Lung Cancer	AZN ASTRAZENECA PLC	Dato-DXd, Osimertinib, Pemetrexed, Carbo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-07 in 17d ESTIMATED	READOUT A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants Phase 1/2 · RSV Respiratory Syncytial Virus	AZN ASTRAZENECA PLC	AZD6489, Licensed RSV vaccine #1, Licens	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Phase 4 · Asthma	AZN ASTRAZENECA PLC	Benralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-23 in 1mo ESTIMATED	READOUT A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combinati Phase 2 · Carcinoma, Non-Small-Cell Lung	AZN ASTRAZENECA PLC	Durvalumab, Tremelimumab, Pemetrexed, Pe	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-27 in 1mo ESTIMATED	READOUT Study of Novel Immunomodulators as Monotherapy and in Combination With Anticance Phase 2 · Hepatocellular Carcinoma, Biliary Tract Cancer	AZN ASTRAZENECA PLC	Volrustomig, Bevacizumab, Lenvatinib, Ri	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adult Phase 3 · Cutaneous Lupus Erythematosus	AZN ASTRAZENECA PLC	Anifrolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-11 in 2mo ESTIMATED	READOUT Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuz Phase 3 · Breast Cancer; HER2-positive; Metastatic	AZN ASTRAZENECA PLC	Trastuzumab deruxtecan, Taxane, Pertuzum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-17 in 2mo ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-24 in 2mo ESTIMATED	READOUT Study of AZD0754 in Participants With Metastatic Prostate Cancer Phase 1/2 · Metastatic Prostate Cancer	AZN ASTRAZENECA PLC	AZD0754, AZD2287	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-10 in 3mo ESTIMATED	READOUT A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Ba Phase 2 · Chronic Kidney Disease and Hypertension	AZN ASTRAZENECA PLC	Baxdrostat/dapagliflozin, Baxdrostat/Pla	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With D Phase 3 · Cancer	AZN ASTRAZENECA PLC	Durvalumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-04 in 4mo ESTIMATED	READOUT A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH Phase 3 · Heterozygous Familial Hypercholesterolaemia	AZN ASTRAZENECA PLC	AZD0780	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2027-01-06 in 4mo ESTIMATED	READOUT Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Phase 3 · Systemic Sclerosis, Scleroderma	AZN ASTRAZENECA PLC	Anifrolumab (blinded), Anifrolumab (unbl	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change